share_log

iBio Inc | 10-K/A: Annual report (Amendment)

iBio Inc | 10-K/A: Annual report (Amendment)

iBio Inc | 10-K/A:年度报表(修正版)
美股SEC公告 ·  09/24 16:17

Moomoo AI 已提取核心信息

iBio Inc, a biotechnology company specializing in AI-driven antibody drug discovery, has reported a net loss from continuing operations of approximately $15.4 million, or $4.03 per share, for the fiscal year ended June 30, 2024. This represents a significant reduction from the previous year's net loss of approximately $29.3 million, or $47.88 per share. The company's total operating expenses also decreased to approximately $16.9 million from $29.3 million in the previous year, primarily due to reduced research and development (R&D) and general and administrative (G&A) expenses. iBio's R&D expenses decreased by about 50% to $5.2 million, while G&A expenses fell by 39% to $11.7 million. The company's revenue for the year was reported at $0.2 million, related to research activities and license fees. iBio...Show More
iBio Inc, a biotechnology company specializing in AI-driven antibody drug discovery, has reported a net loss from continuing operations of approximately $15.4 million, or $4.03 per share, for the fiscal year ended June 30, 2024. This represents a significant reduction from the previous year's net loss of approximately $29.3 million, or $47.88 per share. The company's total operating expenses also decreased to approximately $16.9 million from $29.3 million in the previous year, primarily due to reduced research and development (R&D) and general and administrative (G&A) expenses. iBio's R&D expenses decreased by about 50% to $5.2 million, while G&A expenses fell by 39% to $11.7 million. The company's revenue for the year was reported at $0.2 million, related to research activities and license fees. iBio also highlighted its strategic focus on AI and machine learning to advance its preclinical pipeline in immune-oncology and cardiometabolic diseases. The company has not declared any cash dividends on its common stock and has undergone a reverse stock split to improve its stock price. iBio's future plans include leveraging strategic collaborations, advancing in-house programs, and investing in its AI-technology platform to enhance drug discovery and development. The company also completed the sale of its CDMO facility for $8.5 million and settled its obligations with Woodforest, resulting in a more streamlined operation focused on its core mission.
生物技术公司ibio inc专注于基于人工智能的抗体药物发现,报告了截至2024年6月30日的财政年度持续经营亏损约1540万美元,或每股4.03美元。这相比上一年约2930万美元的净亏损,或每股47.88美元有显着减少。该公司的总营业费用也从上一年的约2930万美元降至约1690万美元,主要是由于研发和一般行政费用的减少。ibio的研发费用下降约50%至520万美元,而一般行政费用降低39%至1170万美元。该年度报告的公司营业收入为20万美元,与研究活动和许可费有关。ibio还强调其战略重点是通过人工智能和机器学习推进其免疫肿瘤学和心脏代谢疾病的临床前研发管线。该公司尚未宣布对其普通股的现...展开全部
生物技术公司ibio inc专注于基于人工智能的抗体药物发现,报告了截至2024年6月30日的财政年度持续经营亏损约1540万美元,或每股4.03美元。这相比上一年约2930万美元的净亏损,或每股47.88美元有显着减少。该公司的总营业费用也从上一年的约2930万美元降至约1690万美元,主要是由于研发和一般行政费用的减少。ibio的研发费用下降约50%至520万美元,而一般行政费用降低39%至1170万美元。该年度报告的公司营业收入为20万美元,与研究活动和许可费有关。ibio还强调其战略重点是通过人工智能和机器学习推进其免疫肿瘤学和心脏代谢疾病的临床前研发管线。该公司尚未宣布对其普通股的现金分红,并进行了一项股票拆分以提高其股价。ibio未来的计划包括利用战略合作关系、推进内部项目,并投资于其人工智能技术平台以增强药物的发现和开发。该公司还以850万美元完成了CDMO设施的出售,并与Woodforest解决了其义务,从而使其更专注于核心使命的经营更加高效。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息